Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

   

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)

The shareholders of Asarina Pharma AB (publ) are hereby summoned to attend the Annual General Meeting (“AGM”) on May 8th, 2019, at 15.00 CET at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 14.30 CET and will stop when the meeting starts. NOTE: This is an unofficial translation of the original notice,…

Full PDF
   

Asarina Pharma shows efficacy of Sepranolone in Tourette’s syndrome on par with current first line treatment, but without side effects

Stockholm, April 2, 2019: Sepranolone reduces tics in an animal model of Tourette’s syndrome on par with Haldol, without inducing any motor side effects.

Full PDF
   

Asarina Pharma Year-End Report 2018 shows solid progress

Stockholm, 25 February, 2019: Asarina Pharma AB releases its Year-End Report including financials for the fourth quarter 2018 and for the full year 2018. (READ THE FULL YEAR-END REPORT IN PDF HERE (http://docs.wixstatic.com/ugd/641552_cd037716c08b48c69d458724079a39d2.pdf).)

Full PDF
AsarinaPharma Q4 YE report-2018final
   

Interim Report July-September 2018

Clinical trials on track Stockholm, 14 November, 2018: Asarina Pharma AB releases its Interim Report for 1 July – 30 September, 2018.

Full PDF
   

Ingen stabilisering av aktier i Asarina Pharma efter noteringen, övertilldelningsoption utnyttjas till fullo

Stockholm – 24 oktober, 2018. Som offentliggjort i samband med erbjudandet av 6 800 000 nya aktier (”Erbjudandet”) i Asarina Pharma AB (publ) och noteringen av Bolagets aktier på Nasdaq First North har Erik Penser Bank (”EPB”) fungerat som stabiliseringsansvarig. I den kapacitet har EPB varit tillåten att genomföra transaktioner i syfte att stödja marknadspriset på aktierna…

Full PDF